 |
|
New study may explain Vioxx side effects
August 28, 2007Vioxx and related pain medications were taken off the market in 2004 because they caused dangerous heart problems in some people. A group of scientists, led by Timothy Hla at the University of Connecticut, may now have figured out how these drugs trigger these life-threatening side-effects. The new study will be published online in the The Journal of Experimental Medicine on August 27.
The target of these drugs is an enzyme called COX-2, which is produced in response to infection or injury and releases pain- and fever-inducing byproducts. Thus blocking COX-2 reduces pain. But blocking Cox-2 in mice, according to the new study, also stimulated the production of a protein called tissue factor, or TF, which initiates blood clotting. As heart attacks and strokes are often triggered by blood clots, it is possible that the production of TF is in part responsible for the drug's adverse side-effects in humans.
In the drug-treated mice, the high levels of TF in the blood were countered by administering TF-reducing drugs. Thus it is theoretically possible to treat people safely with Vioxx and other Cox-2 inhibitors if existing TF-blocking drugs are given simultaneously.
Journal of Experimental Medicine
Journal of Experimental Medicine
Vioxx Current Events and Vioxx News RSSToxic drugs, toxic system: Sociologist predicts drug disasters
Americans are likely to be exposed to unacceptable side effects of FDA-approved drugs such as Vioxx in the future because of fatal flaws in the way new drugs are tested and marketed, according to research to be presented today at the annual meeting of the American Sociological Association (ASA).
Too much information? Study shows how ignorance can be influential
In the current issue of The RAND Journal of Economics, USC researchers provide a challenge to the classic economic model of information manipulation, in which knowing more than anybody else is the key to influence.
Popular Arthritis Drug May Disrupt Heart Rhythm, UB Research Finds
Celebrex, a popular arthritis drug that blocks pain by inhibiting an enzyme known as COX-2, has been shown in laboratory studies to induce arrhythmia, or irregular beating of the heart, via a novel pathway unrelated to its COX-2 inhibition.
FDA petition would protect public from dangerous drugs
In a petition filed today with the U.S. Food and Drug Administration, an international coalition of scientists and doctors seeks to compel the agency to stem the flood of dangerous drugs reaching American consumers by mandating the use of scientifically superior non-animal testing methods when those alternatives exist.
K-State researcher examining why common anti-inflammatory drugs harm intestines
New versions of drugs like buffered aspirin and Vioxx could produce fewer harmful side effects thanks to research being done at Kansas State University's College of Veterinary Medicine.
Combining NSAIDs with chemotherapy, radiation may improve cancer treatment
Until recently, nonsteroidal anti-inflammatory drugs (NSAIDs) like aspirin and celecoxib (sold as Celebrex), were being hailed as promising cancer prevention drugs.
FDA causes unnecessary scare about common painkillers
The U.S. Food and Drug Administration (FDA) has caused an unnecessary scare about some pain relievers by adding a warning to drugs that are safe.
Blood pressure drug shows potential as lung cancer treatment
A hormone that is important in the control of blood pressure also shrinks lung cancer tumors in mice, suggesting a new way to prevent or treat the deadly cancer, according to scientists at Wake Forest University School of Medicine.
Study shows risk of acute pancreatitis low with statins
New research reveals that while cholesterol-lowering drugs do increase the risk of painful inflammation of the pancreas, the side effect is relatively rare, according to Sonal Singh, M.D., from Wake Forest University School of Medicine, and colleagues.
Researchers Uncover a Novel Mechanism of Action of a Potential New Drug for the Treatment of Multiple Sclerosis
Virginia Commonwealth University researchers have identified a unique mechanism of action of a new drug that shows great promise for the treatment of multiple sclerosis.
More Vioxx Current Events and Vioxx News Articles
 | Poison Pills: The Untold Story of the Vioxx Drug Scandal by Tom Nesi To the millions of Americans who suffer from chronic pain and arthritis, Vioxx seemed like a miracle. One of the most widely promoted and prescribed pain medications in the world -- used by more than twenty million people -- it was endorsed by the medical establishment and celebrities such as Olympic champion figure skater Dorothy Hamill. With annual sales of $2.5 billion, Vioxx became a... |
 | Natural Alternatives To Vioxx, Celebrex & Other Anti-inflammatory Prescription Drugs by Carol Simontacchi |
 | Vioxx - A Medical Dictionary, Bibliography, and Annotated Research Guide to Internet References In March 2001, the National Institutes of Health issued the following warning: "The number of Web sites offering health-related resources grows every day. Many sites provide valuable information, while others may have information that is unreliable or misleading." Furthermore, because of the rapid increase in Internet-based information, many hours can be wasted searching, selecting, and... |
| Two COX-2 inhibitors left after Vioxx withdrawal: CV events not linked to other COX-2 drugs.: An article from: Family Practice News by Elizabeth Mechcatie, Peggy Peck This digital document is an article from Family Practice News, published by International Medical News Group on October 15, 2004. The length of the article is 1175 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web... | |
| Pressure building for FDA to mandate post-approval studies after Vioxx incident.(Phase IV studies)(Food and Drug Administration): An article from: Bioresearch Monitoring Alert by Joe Pickett This digital document is an article from Bioresearch Monitoring Alert, published by Washington Information Source on December 1, 2004. The length of the article is 1012 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web... | |
| Fighting for the right to sue.(Legislature)(A law prevents Oregonians from holding the Vioxx maker liable for drug-related deaths): An article from: The Register-Guard (Eugene, OR) This digital document is an article from The Register-Guard (Eugene, OR), published by The Register Guard on May 28, 2005. The length of the article is 1118 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation... | |
| Differing verdicts delivered in early Vioxx cases.(News): An article from: Internal Medicine News by Mary Ellen Schneider This digital document is an article from Internal Medicine News, published by Thomson Gale on December 15, 2005. The length of the article is 637 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle:... | |
| Vioxx's runaway jury.: An article from: Reason by David R. Henderson This digital document is an article from Reason, published by Reason Foundation on December 1, 2005. The length of the article is 566 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle: Vioxx's... | |
| Vioxx withdrawal shakes pharmaceutical industry.(Upfront): An article from: Journal of Dental Hygiene by Daniel Bond This digital document is an article from Journal of Dental Hygiene, published by Thomson Gale on September 22, 2004. The length of the article is 592 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation... | |
| Seguridad para pacientes con artritis.(retirada del mercado del medicamento Vioxx; alternativas para el tratamiento de la artritis): An article from: Siempre! This digital document is an article from Siempre!, published by Edicional Siempre on October 17, 2004. The length of the article is 1826 words. The page length shown above is based on a typical 300-word page. The article is delivered in HTML format and is available in your Amazon.com Digital Locker immediately after purchase. You can view it with any web browser.Citation DetailsTitle: Seguridad... |
| © 2008 BrightSurf.com |